• Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
    Nov 21 2024

    Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
    Show More Show Less
    19 mins
  • Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
    Oct 24 2024

    Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
    Show More Show Less
    21 mins
  • Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
    Sep 5 2024

    Interview with Eileen M. O’Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
    Show More Show Less
    17 mins
  • Identification of Immune Checkpoint Inhibitor–Induced Diabetes
    Aug 29 2024

    Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Identification of Immune Checkpoint Inhibitor–Induced Diabetes
    Show More Show Less
    15 mins
  • Neoadjuvant Exercise Therapy in Prostate Cancer
    Jul 18 2024

    Interview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Neoadjuvant Exercise Therapy in Prostate Cancer
    Show More Show Less
    19 mins
  • Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black Individuals
    Jun 27 2024

    Interview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals
    Show More Show Less
    15 mins
  • T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
    Apr 18 2024

    Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD.

    Related Content:

    • T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
    Show More Show Less
    20 mins
  • Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
    Mar 21 2024

    Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
    Show More Show Less
    26 mins